1.
Open Forum Infect Dis
; 9(8): ofac349, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1985109
ABSTRACT
Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14-607 days pre-blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.